Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDOPA Uptake
NCT07542158Phase 2Enrolling by invitation
- Sponsor
- Akiva Mintz
- Start
- May 2025
- Primary completion
- Jun 2030
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of Fluorodopa F 18 in parkinsonian syndromes, neuroendocrine tumors (NETs), glioma, sponsored by Akiva Mintz. Started May 2025; status: enrolling by invitation.
02
Drugs
Fluorodopa F 18
03
Conditions
parkinsonian syndromesneuroendocrine tumors (NETs)glioma
Beyond the preview
Go deeper on NCT07542158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542158.